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ARTICLE
CNVs leading to fusion transcripts in individuals
with autism spectrum disorder
Richard Holt1, Nuala H Sykes1, Ineˆs C Conceic¸a˜o2,3,4, Jean-Baptiste Cazier1, Richard JL Anney5,
Guiomar Oliveira6,7,8, Louise Gallagher5, Astrid Vicente2,3,4, Anthony P Monaco1 and Alistair T Pagnamenta*,1
There is strong evidence that rare copy number variants (CNVs) have a role in susceptibility to autism spectrum disorders
(ASDs). Much research has focused on how CNVs mediate a phenotypic effect by altering gene expression levels. We
investigated an alternative mechanism whereby CNVs combine the 50 and 30 ends of two genes, creating a ‘fusion gene’.
Any resulting mRNA with an open reading frame could potentially alter the phenotype via a gain-of-function mechanism.
We examined 2382 and 3096 rare CNVs from 996 individuals with ASD and 1287 controls, respectively, for potential to
generate fusion transcripts. There was no increased burden in individuals with ASD; 122/996 cases harbored at least one rare
CNV of this type, compared with 179/1287 controls (P¼0.89). There was also no difference in the overall frequency
distribution between cases and controls. We examined specific examples of such CNVs nominated by case–control analysis and
a candidate approach. Accordingly, a duplication involving REEP1-POLR1A (found in 3/996 cases and 0/1287 controls) and a
single occurrence CNV involving KIAA0319-TDP2 were tested. However, no fusion transcripts were detected by RT-PCR.
Analysis of additional samples based on cell line availability resulted in validation of a MAPKAPK5-ACAD10 fusion transcript in
two probands. However, this variant was present in controls at a similar rate and is unlikely to influence ASD susceptibility.
In summary, although we find no evidence that fusion-gene generating CNVs lead to ASD susceptibility, discovery of a
MAPKAPK5-ACAD10 transcript with an estimated frequency of B1/200 suggests that gain-of-function mechanisms should
be considered in future CNVs studies.
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INTRODUCTION
Copy number variants (CNVs) are deletions or duplications of
chromosomal segments ranging from a few thousand to several
million base pairs. A number of population-based studies have shown
that this type of genomic variant can affect as much as 12% of the
human genome.1 Many studies have gone on to demonstrate the
importance of CNVs in determining human phenotypic variation and
disease susceptibility.2,3
The Autism Genome Project consortium (AGP) recently detected
an excess of genes disrupted by rare CNVs in 996 individuals with
autism spectrum disorder (ASD) in comparison to 1287 control
subjects.4 This increased burden demonstrates the relevance of CNVs
in susceptibility to this early-onset neurodevelopmental condition.
Unlike some other studies, where exceptionally rare homozygous
CNVs were seen in long tracts of homozygosity-by-descent,5 the AGP
cohort contains very few consanguineous ASD pedigrees and
therefore the vast majority of these rare CNVs are heterozygous.
Studies on both humans and mice have shown that CNVs can
influence gene expression.6,7 This has led many scientists to
hypothesize that these heterozygous CNVs may influence
susceptibility to neurodevelopmental disorders through a gene-
dosage mechanism. For instance, it is easy to imagine how mild
perturbations in axon guidance molecules could affect critical stages
of brain development. Others have looked for evidence of an
alternative mechanism whereby deletions might unmask recessive
coding changes in the opposite allele.8,9,10
A third possible mechanism exists for deletions or duplications
with breakpoints disrupting two different genes. Where the two
neighboring genes are encoded on the same chromosomal strand,
such CNVs could potentially result in gene-fusion transcripts.
A number of genomic rearrangements that lead to fusion transcripts
have already been described in autism and schizophrenia.11,12,13
If such transcripts are stable they may be translated into novel
proteins with a possibility for deleterious gain-of-function effects.
Fusion-proteins have an important role in cancer genetics, most
notably in leukemia, and can result from chromosomal translocation
(eg BCR-ABL fusion gene on the Philadelphia chromosome). Somatic
deletions of chromosome 21 have also been shown to result in
TMPRSS2-ERG fusion transcripts in the majority of prostate can-
cers,14 and the exact configuration of these transcripts appears to
correlate with clinical outcome.15 However, to our knowledge, there
have been few systematic studies determining the frequency with
which germline deletions and duplications can similarly lead to fusion
genes/proteins (Figure 1a and b). Therefore, to address the question
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of how common CNV-induced fusion transcripts are and to assess
whether this type of CNV may have a role in ASD susceptibility,
we carried out a bioinformatic analysis of existing CNV calls based on
published 1M SNP array data.4 Validation of specific instances of such
CNVs was then attempted using RT-PCR.
MATERIALS AND METHODS
CNV calls
CNVs were called as part of a previous AGP study.4 Briefly, DNA from
individuals with ASD, parents and controls were genotyped using the Infinium
1M-single SNP microarray (Illumina, San Diego, CA, USA). High confidence
CNVs were predicted by intersecting CNV calls from both iPattern and
QuantiSNP algorithms (log Bayes Factor415). Previous analysis showed that
validation rates were B95% for CNVs identified using this method.4 From
these data, rare CNV calls, present at o1% of the combined sample, and
greater than 30kb in size were identified from a total of 996 cases and 1287
controls (all Caucasian). For CNVs of interest, raw SNP data was reviewed
manually using BeadStudio version 3.0 (Illumina) (Figure 1c).
Bioinformatic analyses
We used a bioinformatics approach to identify CNVs that show evidence of the
breakpoints disrupting two different genes on the same strand. The following
steps were applied: because of the relatively high density of SNPs compared to
the size of the genes, the identified boundaries of the CNV were considered
to be sufficiently exact. Those boundaries were tested against the location of
RefSeq genes (NCBI build36/hg18) for overlap. Pairs of genes, transcribed in
the same direction, and each containing an extremity of a CNV were flagged
and counted. This selection also marked all intermediate genes in the same
direction. The procedure was performed independently in the case and control
groups. It was therefore possible to compare the number of times a group of
genes was affected by a CNV between the two groups.
To determine whether the MAPKAPK5-ACAD10 and POLR1A-REEP1
duplications were ancestral, present on a single haplotype, genotype data for
each trio was extracted from BeadStudio. Genotypes were phased for a total of
100 SNPs flanking the duplication (50 on either side or else until the shared
haplotype finished). Haplotypes upon which the duplication was observed
were then compared.
Quantitative PCR of CNV involving SHANK3
For family 3379, quantitative PCRs were performed in triplicate using the iQ
SYBR Green Supermix (BioRad, Hercules, CA, USA), 0.2mM of each primer
and 20 ng of template DNA in a total reaction volume of 25ml. Thermocycling
and data acquisition was carried out using the iQ5 iCycler (BioRad).
Primers sets for SHANK3 targeted intron 3, exon 10, exon 16 and intron
19 are as described.16 A control amplicon in the MAPK1 gene on chromosome
22q11.2 was also included.
Fine mapping the duplication involving REEP1 and POLR1A
Long-range PCR was performed using primers 50-GATATTGCTGCCCTTCTT
GG-30 and 50-TGCAAAGAGCCAGCCTAGTT-30 and the SequalPrep Long
PCR kit (Invitrogen, Eugene, OR, USA) according to the manufacturer’s
suggested protocol. PCR products were purified using exonuclease I (NEB,
Ipswich, MA, USA) and shrimp alkaline phosphatase (USB, Cleveland, OH,
USA). Sanger sequencing of the junction fragment was then performed using
BigDye chemistry (Applied Biosystems, Foster City, CA, USA). The forward
PCR primer was sufficiently close to reach the breakpoint (Supplementary
Figure 1a).
Fine mapping the duplication involving KIAA0319 and TDP2
Long-range PCR was performed using primers 50-ACGAGATGTGGCCAAAG
TAG-30 and 50-ATTCTTGTTCTATTTGGCAGAC-30 and the BIO-X-ACT long
DNA polymerase kit (Bioline, London, UK) according to the manufacturer’s
suggested protocol. Sequencing was performed as described above, with each
PCR primer and also an internal primer (50-ACCTAATATTGAGTGTTTATG
C-30) that was required to reach the breakpoint (Supplementary Figure 1b).
RNA extraction and cDNA synthesis
EBV-transformed peripheral lymphoblast cell lines (LCLs) were available for a
subset of patients. Cells were grown in RPMI 1640 media supplemented with
10% fetal bovine serum (Invitrogen), L-glutamine (final concentration 2mM)
and penicillin (500U/ml) and streptomycin (5mg/ml). RNA was extracted
using the RNeasy kit (Qiagen, Crawley, UK) and cDNA was synthesized using
the QuantiTect reverse transcriptase kit (Qiagen) according to the manufac-
turer’s suggested protocol, using approximately 1mg of RNA as template.
RT-PCR and sequencing
PCR primers were designed in exons closest to the CNV breakpoints, following
manual inspection of log R ratios and allelic ratio data within BeadStudio.
All CNVs tested were duplications; therefore the primers were designed as
indicated (Figure 1b; Supplementary Figure 1a-e). For CNVs where the
breakpoints were not clear, multiple primer combinations were tested. Primer
sequences are listed in Supplementary Table 1.
Thirty five cycles of PCR amplification were performed in a 20-ml volume,
with 0.5ml of cDNA as template, a final Mg2þ concentration of 1.5mM, each
primer at 200 nM and the BIOTAQ DNA polymerase (Bioline). The gene
encoding beta-actin (ACTB) was used as a control. PCR products were
visualized by UV illumination of 1.8% agarose gels stained with SYBR Safe
(Invitrogen). Sequencing was performed as described above.
Expression analysis of the 50 genes
To test whether the promoters of the genes comprising the 50 end of the
putative fusion transcripts were active in LCLs, cDNA was generated (detailed
above). Primers were designed for the 50 gene of the putative fusion product
(Supplementary Table 1) and RT-PCR performed, with ACTB used as a
positive control. PCRs were typically carried out using the PCR conditions
described above. An annealing temperature of 55 1C was used in all instances
except ACTB (56 1C). Expression was determined by the detection of a single
band of the predicted size.
The various analysis strategies employed are also summarized in
Supplementary Figure 2.
RESULTS
Genome-wide analysis of fusion CNV frequency
In a previous study analyzing 996 individuals with ASD, a total of
2382 rare CNVs present in 889 individuals were observed.4 Similarly,
in 1287 control subjects, there were 3096 rare CNVs present in 1146
individuals. From these, we assessed which of these variants had the
potential to lead to a fusion transcript. Intersecting CNVs with RefSeq
gene coordinates indicated that 134/2382 (5.6%) and 200/3096
(6.5%) of rare CNVs could lead to fusion transcripts in cases and
controls, respectively. Reported at the individual level, 122/996
ASD cases harbored at least one rare CNV of this type, compared
with 179/1287 control subjects (P¼ 0.89, Fisher’s Exact Test). The
frequencies distribution of putative fusion transcript forming CNV
was not significantly different in cases compared with controls
(P40.05; Supplementary Figure 3). The synapse is known to be of
importance in ASD susceptibility. We therefore compared the
frequency between cases and controls of putative fusion transcript
forming CNVs involving at least one gene expressed in the human
post-synaptic density.17 However, no significant difference was
observed (P40.05).
Despite the lack of a genome-wide increase in burden of potential
fusion-gene generating CNVs in ASD, specific instances could still be
of potential significance. Therefore, we further examined this class of
CNV at single loci.
REEP1-POLR1A fusion gene
Initially, we decided to further examine individual putative fusion-
gene generating CNVs based on differences in distribution between
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cases and controls. The CNV closest to reaching significance was a
duplication on chromosome 2. This CNV was present in 3/996 cases
(probands from families 13 131, 13 129, 14 284) and 0/1287 controls
(P¼ 0.08, Fisher’s Exact Test). Analysis of SNP data indicated that the
duplications were on the same haplotype (data not shown) and thus
likely to represent an ancient ancestral event. Fine mapping experi-
ments were carried out in family 14 284 that indicated the duplication
was a direct tandem repeat involving chr2:86 136 225–86 364 443
(Figure 2a). This rearrangement thus fuses the 30 end of REEP1 with
the 50 end of POLR1A. Forward and reverse RT-PCR primers were
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Figure 1 Detection of CNVs that may lead to fusion transcripts. (a) Schematic diagram showing two neighboring genes (blue and green) encoded on the
same chromosomal strand. Black arrows show hypothetical position of exonic primers. Below, a deletion leads to a fusion gene whereby, upon transcription,
the primers are close enough for efficient RT-PCR amplification to take place. (b) As above, but instead showing a tandem duplication. N.B. As well as the
fusion gene, there is one functional copy of both genes on the mutated chromosome. (c) BeadStudio screenshot showing raw Log R Ratio and B allele
frequency for a duplication on chromosome 12 in sample 3044.6. The duplication results in an increase to the Log R ratio and deviation in the allelic ratio
for heterozygote variants away from the expected 0.5. Breakpoints disrupt different genes, encoded on the same chromosomal strand. SNPs within the
duplication are highlighted in red. Region shown is chr12:110 600000–110 900 000 (NCBI36/hg18).
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designed in REEP1 and POLR1A (Supplementary Figure 1a) and
tested using cDNA from family 14 284 (the one family for whom
cDNA was available; in this family the father and proband carry the
variant). However, all primer combinations tested failed to generate a
PCR product.
Candidate gene approach
Next, we identified two CNVs as being of potential interest owing to
the presence of genes strongly implicated in neurodevelopmental
disorders. The first was a 96-kb putative de novo duplication of 22q13
in individual 3379.3 with predicted breakpoints in SHANK3 and
RPL23AP82 (Table 1). SHANK3 is a known ASD susceptibility
gene.16,18,19 However, closer examination of the SNP genotype data
indicated that the CNV call was likely to be a false positive. This was
confirmed by qPCR analysis of genomic DNA (data not shown).
The second CNV was an inherited duplication on 6p22.2 in Irish
subject 13 083.973. This was predicted to fuse the first exon of
KIAA0319 with the 30 end of the neighboring gene TDP2. KIAA0319
is a dyslexia susceptibility gene20,21,22 and there is known overlap of
susceptibility CNVs between different neurodevelopmental
disorders.23,24 The resolution of the CNV in the 1M SNP data was
sufficient to design long-range PCR primers and subsequent PCR
confirmed the presence of the CNV as a tandem duplication in the
proband and mother. PCR products were sequenced and the
duplicated segment identified as chr6:24 728 714–24 766 602
(Figure 2a). Therefore, the CNV would fuse the first noncoding exon
of KIAA0319 with exons 4–7 of TDP2. It is unclear whether a viable
open reading frame would result from a transcript with this
combination of exons. EBV-transformed LCLs were obtained for
both individuals carrying the CNV and used to generate cDNA.
However, no fusion transcript was detectable by RT-PCR.
Identification of an expressed fusion transcript
None of the previous three CNVs examined above generated a bone
fide fusion transcript. However, to confirm that this class of CNV can
generate fusion transcripts in our cohort, we screened another subset
of putative fusion genes. The 134 rare CNVs with potential to cause
fusion transcripts were filtered for those present in cases from the
Figure 2 Further characterization of CNVs of interest and validation of a fusion transcript. (a) Sequencing electropherogram showing genomic breakpoints
for the KIAA0319-TDP2 and POLR1A-REEP1 duplications. (b) Results from RT-PCR analysis of RNA from four cell lines (two probands and two controls).
The band at 243 bp indicates that the predicted fusion transcript is present. For each sample a positive and negative RT control was included (þ and 
symbols, respectively). (c) Pedigrees showing the segregation pattern of the MAPKAPK5-ACAD10 duplication in families 3044 and 3075. Presence of the
fusion transcript duplication is highlighted in red. Arrows indicate the proband. (d) Sequencing electropherogram further validated the MAPAPK5-ACAD10
fusion transcript, with predicted reading frame shown above.
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International Molecular Genetic Study of Autism Consortium
(IMGSAC) cohort, for which we had direct access to LCLs. This
identified 19 CNVs from 18 different families (Table 1). The 1M SNP
genotyping results for these CNVs were assessed manually within
BeadStudio. A number of these (including the putative duplication
involving SHANK3) appeared to be likely false positive CNV calls due
to noisy SNP data or gaps in coverage on the 1M array. Therefore, cell
lines from four families harboring the three CNVs with the strongest
evidence from the genotyping data were tested to identify fusion
transcripts. Cell lines for probands were cultured, RNA extracted and
used to generate cDNA. Primers were then designed to span between
the two genes in the potential fusion transcript.
We were unable to detect transcripts for the CNVs fusing SLC38A8-
MBTPS1 or DSG3-DSG4 from the probands of families 3199 and
3309, respectively. A PCR product was obtained for samples from
families 3044 and 3075 showing that the B130-kb duplication on
chromosome 12, joining the 50 end of MAPKAPK5 and the 30 end of
ACAD10, does lead to a bone fide fusion transcript (Figure 2b).
Analysis of other family members confirmed that this CNV had been
inherited by the probands’ affected sibling in both families, as well as
one unaffected brother in family 3044 (Figure 2c). Sequencing of the
PCR products showed the transcript runs from exon 7 ofMAPKAPK5
to exon 13 of ACAD10. The ACAD10 portion of this novel transcript
is out of frame and predicted to lead to 13 new amino acids followed
by a stop codon (Figure 2d). Analysis of the SNPs flanking the
duplication in all three IMGSAC families showed the duplication
bearing haplotype to be identical, indicating the CNV was ancestral
(Supplementary Table 2). Overall this CNV was seen in 5/996 (0.5%)
of cases and 5/1287 (0.4%) of controls.
Confirmation of gene expression in lymphoblasts
One potential explanation for the lack of observation of fusion
transcripts was that the promoter of the 50 gene is simply not active in
LCLs. Therefore, we extracted RNA from control LCLs and subse-
quently generated cDNA. Transcripts were detected for POLR1A,
KIAA0319 and DSG3. However, we were unable to detect expression
of SLC38A8. Thus, in the majority of cases examined, if a fusion
transcript were generated, we would expect to observe it using the
methods employed here.
DISCUSSION
In this study, we have assessed whether CNVs that lead to fusion
transcripts may have a role in susceptibility to ASD. To do this
we integrated CNV and RefSeq gene coordinates, looking for
CNVs where the breakpoints intersect two different genes that are
transcribed in the same direction. Our analysis indicates that there is
no increased burden of this type of CNV in 996 cases compared with
1287 controls.
The sample size currently available gives our study limited power to
detect association of CNVs at specific loci. For instance, in our
analysis, the CNV closest to reaching significance involved the REEP1
and POLR1A genes and reached P¼ 0.08. POLR1A and REEP1
encode polymerase (RNA) I polypeptide A and a mitochondrial
receptor accessory protein, respectively. Interestingly, dominant
mutations of REEP1 lead to autosomal-dominant hereditary spastic
paraplegia, and a recent study described a similar duplication
involving exons 2–7 as part of the mutational spectrum of this
gene.25 It is possible that the loss of POLR1A 30-regulatory elements in
the fusion gene may lead to a loss of expression in LCLs, but that
expression might still occur in other cell types. However, no other
tissue types were available from the families to test this hypothesis.
Therefore, this CNV may still potentially have a role in ASD
susceptibility through our hypothesized mechanism.
Investigation of two candidate CNVs based on the previous
identification of the genes involved in neurodevelopmental disorders
indicated that neither were likely to be involved in ASD susceptibility
through our hypothesized mechanism. The putative de novo duplica-
tion on chromosome 22q, involving SHANK3 and RPL23AP82, was
assessed by qPCR and shown to be a false positive. This finding
illustrates one significant limitation of this study – that although two
separate CNV detection algorithms were used to improve the
confidence of CNV calling,4 upon closer examination, a proportion
of the potentially fusion transcript forming CNV calls appeared to be
imprecise in terms of breakpoints or else are false positives.
Table 1 CNVs identified in probands from the IMGSAC cohort with potential to result in a fusion transcript
Chr Start End Size Gene 1 Gene 2 Family ID Type
2 32 483 938 33184 723 700 785 BIRC6 LTBP1 3022 Dup
2 110 206 673 110 615 080 408 407 MALL LIMS3-LOC440895 3181 Del
2 110 206 673 110 615 080 408 407 MALL LIMS3-LOC440895 3266 Del
2 110 206 673 110 615 080 408 407 MALL LIMS3-LOC440895 3049 Del
2 170 311 824 170 375 059 63235 KLHL23 SSB 3423 Del
4 1 711 332 1 779 448 68116 TACC3 FGFR3 3228 Dup
5 37 274 997 37349 755 74758 NUP155 C5orf42 3267 Dup
5 70 274 080 70451 560 177 480 SMN1 SMN2 3020 Dup
6 167 143 252 167 264 573 121 321 RNASET2 RPS6KA2 3303 Dup
9 138 488 774 139 538 498 1 049 724 PNPLA7 SEC16A 3228 Dup
12 110 665 461 110 799 555 134 094 ACAD10 MAPKAPK5 3044 Dup
12 110 665 461 110 799 555 134 094 ACAD10 MAPKAPK5 3436 Dup
12 110 666 628 110 799 555 132 927 ACAD10 MAPKAPK5 3075 Dup
16 82 604 216 82684 284 80068 MBTPS1 SLC38A8 3199 Dup
17 30 708 148 30792 312 84164 SLFN13 SLFN11 3431 Del
18 27 222 369 27305 675 83306 DSG3 DSG4 3309 Dup
19 46 041 879 46073 380 31501 CYP2A7 CYP2A6 3304 Dup
19 46 041 879 46073 380 31501 CYP2A7 CYP2A6 3435 Del
22 49 486 044 49582 267 96223 RPL23AP82 SHANK3 3379 Dup
For those in bold, we attempted to experimentally validate the presence of a fusion transcript.
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Comparative studies have shown that there is still a surprising
amount of variation between CNV calling algorithms, even when
using the same raw data.26 Further work to improve CNV calling
algorithms would in turn improve accuracy of predicting CNVs that
may lead to fusion transcripts. In contrast, the duplication involving
KIAA0319 (a susceptibility gene for dyslexia) was validated using
genomic DNA, although no fusion transcript was identified.
In this study, a fusion transcript involving the MAPKAPK5 and
ACAD10 genes was validated in two multiplex families. In both
families tested, this chromosome 12 duplication and associated
transcript were present in the probands’ affected sibling, as well as
an unaffected brother in family 3044 (Figure 2c). However, sequen-
cing indicated that the transcript had a premature stop codon and so
may be degraded by nonsense-mediated decay. Within the whole AGP
study, this variant was seen at a similar frequency in cases and
controls. Thus, it is unlikely to have relevance to ASD susceptibility.
It is interesting to note that ALDH2 (encoding the aldehyde
dehydrogenase 2 enzyme) is fully contained within this duplication.
This gene is known to influence alcohol sensitivity27 and risk for
esophageal cancer,28 and so it may be that this duplication confers
some protection against these two conditions. The ancestral nature of
this duplication suggests it is likely to be imputable in GWAS analysis,
making this hypotheses easily testable.
One potential weakness in our attempts to confirm the presence or
absence of fusion transcripts is the use of cDNA generated from LCLs,
as opposed to cell types more directly related to ASD. However, work
by Baron et al29 has suggested that LCLs are suitable substitutes and
several studies have used them to investigate ASD risk factors.30,31
There are a number of reasons why 80% of the CNVs tested may
not have resulted in detectable fusion transcripts. As discussed earlier,
the gene making up the 50 end of fusion product may not be
expressed in LCLs. Our RT-PCR analyses appear to rule this
possibility out for three of the CNVs (although it must be noted
that large CNVs might alter chromatin structure). Second, it may be
that the loss of 30 control elements from the 50 fused gene may alter
expression, such that the fused product is not seen in LCLs. This may
be the case with the POLR1A-REEP1 and KIAA0319-TDP2 CNVs.
Third, it could be that fusion transcripts are expressed, but at levels
below the sensitivity of the RT-PCR method used here. Fourth, the
neighboring splice donor and acceptor sites may simply be incompa-
tible and so may result either in unexpected cryptic transcripts
(a possibility that could be addressed in future studies by the use of
30-RACE or RNAseq) or else in a total absence of fusion transcript.
Fifth, the resolution of CNV breakpoints may not have been
sufficiently accurate to enable suitable primers to be designed. Finally,
as all these CNVs happened to be duplications, we could not always
be sure that the duplicated DNA was not present at a different
genomic locus. The exception to the last two points are the POLR1A-
REEP1 and KIAA0319-TDP duplications, where fine-mapping con-
firmed the CNVs to be in a direct tandem orientation (Figure 2a).
In conclusion, our data do not lend support to the hypothesis that
gain-of-function fusion genes are a common mechanism for ASD
susceptibility. However, larger data sets are required to better assess
individual loci. Our characterization of a MAPAPK5-ACAD10 fusion
transcript is consistent with other studies showing that rare germline
CNVs can lead to fusion transcripts. Therefore, fusion genes and
gain-of-function mechanisms should still be considered in future
studies of genomic imbalance and disease susceptibility.
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